Antiviral activity of a polysaccharide from Radix Isatidis (Isatis indigotica Fortune) against hepatitis B virus (HBV) in vitro via activation of JAK/STAT signal pathway.
Antiviral Agents
/ pharmacology
Cell Survival
/ drug effects
DNA, Viral
/ drug effects
Drugs, Chinese Herbal
/ pharmacology
Hep G2 Cells
Hepatitis B
/ drug therapy
Hepatitis B Surface Antigens
/ metabolism
Hepatitis B virus
/ drug effects
Humans
Janus Kinases
/ metabolism
Polysaccharides
/ pharmacology
STAT1 Transcription Factor
/ metabolism
Anti-hepatitis B virus (HBV)
JAK/STAT signal Pathway
Radix isatidis (Isatis tinctoria Fortune) polysaccharide
Journal
Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310
Informations de publication
Date de publication:
15 Jul 2020
15 Jul 2020
Historique:
received:
08
10
2019
revised:
19
03
2020
accepted:
19
03
2020
pubmed:
29
3
2020
medline:
20
2
2021
entrez:
29
3
2020
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) infection frequently results in both acute and chronic hepatitis and poses serious threats to human health worldwide. Despite the availability of effective HBV vaccine and anti-HBV drugs, apparently inevitable side effects and resistance have limited its efficiency, thus prompt the search for new anti-HBV agents. The traditional Chinese medicine Radix Isatidis has been used for thousands of years, mainly for the treatment of viral and bacterial infection diseases including hepatitis. In this study, antiviral activities of a Radix Isatidis (Isatis indigotica Fortune) polysaccharide (RIP) were evaluated in vitro model using the HepG2.2.15 cell line and the underlying mechanism was elucidated with the aim of developing a novel anti-HBV therapeutic agent. Structure features of the purified polysaccharide RIP were investigated by a combination of chemical and instrumental analysis. Drug cytotoxicity was assessed using the MTT assay. The contents of HBsAg, HBeAg, intracellular and extracellular IFN-α level were measured using respective commercially available ELISA kit. The HBV DNA expression was evaluated by real-time quantitative polymerase chain reaction (PCR) and the relevant proteins involved in TFN/JAK/STAT signaling pathways were examined by western blot assay. MTT assay showed that RIP had no toxicity on HepG2.2.15 cell line below the concentration 400 μg/ml at Day 3, 6 and 9. Furthermore, RIP at the concentration of 50, 100 and 200 μg/ml significantly reduced extracellular and intracellular level of HBsAg, HBeAg and HBV DNA in HepG2.2.15 cells in a time and dose-dependent manner. Moreover, RIP also enhanced the production of IFN-α in HepG2.2.15 cell via activation of JAK/STAT signal pathway and induction of antiviral proteins, as evidenced by the increased protein expression of p-STAT-1, p-STAT-2, p-JAK1, p-TYK2, OAS1, and Mx in HepG2.2.15 cells. In addition, the over expression of SOCS-1 and SOCS-3 was significantly abolished under same conditions. These results suggested that the HBV inhibitory effect of RIP was possibly due to the activation of IFN-α-dependent JAK/STAT signal pathway and induction of the anti-HBV protein expression.
Identifiants
pubmed: 32217096
pii: S0378-8741(19)34042-5
doi: 10.1016/j.jep.2020.112782
pii:
doi:
Substances chimiques
Antiviral Agents
0
DNA, Viral
0
Drugs, Chinese Herbal
0
Hepatitis B Surface Antigens
0
Polysaccharides
0
STAT1 Transcription Factor
0
banlangen
8S10GFI6DX
Janus Kinases
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112782Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors declare that they have no conflicts of interest with regard to the contents of this article.